Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.54 |
| ▸ | EYA2 | O00167 | 1/20 | 0.54 |
| ▸ | APP | P05067 | 1/20 | 0.54 |
| ▸ | ACE | P12821 | 1/20 | 0.54 |
| ▸ | BLM | P54132 | 2/20 | 0.52 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.52 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | DRD1 | P21728 | 1/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.52 |
| ▸ | DRD3 | P35462 | 1/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2597699 | 1.00 | TDP1 (0.54) | TDP1EYA2APPACEBLM | |
| SCHEMBL3487367 | 1.00 | TDP1 (0.54) | TDP1EYA2APPACEBLM | |
| SCHEMBL3001043 | 1.00 | TDP1 (0.54) | TDP1EYA2APPACEBLM | |
| SCHEMBL24732403 | 1.00 | TDP1 (0.54) | TDP1EYA2APPACEBLM | |
| SCHEMBL2995896 | 1.00 | TDP1 (0.54) | TDP1EYA2APPACEBLM | |
| SCHEMBL24732405 | 1.00 | TDP1 (0.54) | TDP1EYA2APPACEBLM | |
| Edetic Acid SCHEMBL9793636 | 0.96 | TDP1 (0.58) | TDP1EYA2APPACEBLM | |
| Edetic Acid SCHEMBL8207533 | 0.96 | TDP1 (0.58) | TDP1EYA2APPACEBLM | |
| Edetic Acid SCHEMBL1275068 | 0.96 | TDP1 (0.58) | TDP1EYA2APPACEBLM | |
| SCHEMBL19962167 | 0.94 | TDP1 (0.42) | TDP1EYA2APPACEBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3570897-B1 | RADIOIMMUNOCONJUGATE FOR USE IN TREATING BONE MARROW ASSOCIATED DISEASES | THERAPHARM GMBH (CH) | 2023-10-04 | — | — | EP | claimed |
| US-20220401594-A1 | RADIOIMMUNOCONJUGATE FOR USE IN TREATING BONE MARROW ASSOCIATED DISEASES | THERAPHARM GMBH (CH) | 2022-12-22 | — | — | US | claimed |
| WO-2018134430-A1 | RADIOIMMUNOCONJUGATE FOR USE IN TREATING BONE MARROW ASSOCIATED DISEASES | THERAPHARM GMBH (CH) | 2018-07-26 | — | — | WO | claimed |
| EP-3351271-A1 | RADIOIMMUNOCONJUGATE FOR USE IN TREATING BONE MARROW ASSOCIATED DISEASES | TheraPharm GmbH (CH) | 2018-07-25 | — | — | EP | claimed |
| EP-1962913-B1 | RADIOIMMUNOCONJUGATE FOR HUMAN CD66 FOR THE TREATMENT OF MULTIPLE MYELOMA | THERAPHARM GMBH (CH) | 2013-12-04 | — | — | EP | claimed |
| US-20100183505-A1 | IMMUNOCONJUGATE FOR HUMAN CD66 FOR THE TREATMENT OF MULTIPLE MYELOMA AND OTHER HAEMATOLOGICAL MALIGNANCIES | THERAPHARM GMBH | 2010-07-22 | — | — | US | claimed |
| US-20250032652-A1 | STABILIZED RADIOPHARMACEUTICAL COMPOSITION | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2025-01-30 | — | — | US | disclosed |
| EP-4442285-A1 | STABILIZED RADIOPHARMACEUTICAL COMPOSITION | Nihon Medi-Physics Co., Ltd. (JP) | 2024-10-09 | — | — | EP | disclosed |
| EP-4397320-A1 | RADIOACTIVE COMPLEX OF DEGLYCOSYLATED ANTIBODY AND RADIOACTIVE PHARMACEUTICAL PRODUCT | Nihon Medi-Physics Co., Ltd. (JP) | 2024-07-10 | — | — | EP | disclosed |
| US-20240207464-A1 | RADIOACTIVE COMPLEX OF ANTI-CD20 ANTIBODY, AND RADIOPHARMACEUTICAL | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2024-06-27 | — | — | US | disclosed |
| US-20240207463-A1 | RADIOACTIVE COMPLEX OF ANTI-EGFR ANTIBODY, AND RADIOPHARMACEUTICAL | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2024-06-27 | — | — | US | disclosed |
| EP-4327831-A1 | RADIOACTIVE COMPLEX OF ANTI-CD20 ANTIBODY, AND RADIOPHARMACEUTICAL | Nihon Medi-Physics Co., Ltd. (JP) | 2024-02-28 | — | — | EP | disclosed |
| EP-4317188-A1 | RADIOACTIVE COMPLEX OF ANTI-EGFR ANTIBODY, AND RADIOPHARMACEUTICAL | Nihon Medi-Physics Co., Ltd. (JP) | 2024-02-07 | — | — | EP | disclosed |
| WO-2018134430-A1 | RADIOIMMUNOCONJUGATE FOR USE IN TREATING BONE MARROW ASSOCIATED DISEASES | THERAPHARM GMBH (CH) | 2018-07-26 | — | — | WO | disclosed |
| EP-3351271-A1 | RADIOIMMUNOCONJUGATE FOR USE IN TREATING BONE MARROW ASSOCIATED DISEASES | TheraPharm GmbH (CH) | 2018-07-25 | — | — | EP | disclosed |
| US-9072797-B2 | Immunoconjugate for human CD66 for the treatment of multiple myeloma and other haematological malignancies | THERAPHARM GMBH (CH) | 2015-07-07 | — | — | US | disclosed |
| WO-2011144744-A1 | TARGETED RADIOACTIVE COMPOUND FOR HUMAN CD66 FOR THE TREATMENT OF DISORDERS | THERAPHARM GMBH (CH) | 2011-11-24 | — | — | WO | disclosed |
| US-20100183505-A1 | IMMUNOCONJUGATE FOR HUMAN CD66 FOR THE TREATMENT OF MULTIPLE MYELOMA AND OTHER HAEMATOLOGICAL MALIGNANCIES | THERAPHARM GMBH | 2010-07-22 | — | — | US | disclosed |
| EP-1962913-A2 | RADIOIMMUNOCONJUGATE FOR HUMAN CD66 FOR THE TREATMENT OF MULTIPLE MYELOMA | Therapharm GmbH (CH) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007062855-A2 | RADIOIMMUNOCONJUGATE FOR HUMAN CD66 FOR THE TREATMENT OF MULTIPLE MYELOMA | THERAPHARM GMBH (CH) | 2007-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240207464-A1 | RADIOACTIVE COMPLEX OF ANTI-CD20 ANTIBODY, AND RADIOPHARMACEUTICAL | CD209, TFRC, FCGR2A | TDP1 4256/4885EYA2 4840/4885APP 3647/4885 |
| US-20220401594-A1 | RADIOIMMUNOCONJUGATE FOR USE IN TREATING BONE MARROW ASSOCIATED DISEASES | FCGR2A, FCGR3B, BST2 | TDP1 2526/4885EYA2 2637/4885APP 900/4885 |
| US-20250032652-A1 | STABILIZED RADIOPHARMACEUTICAL COMPOSITION | TST, MPST, TMEM14C | TDP1 2685/4885EYA2 3078/4885APP 2988/4885 |
| US-20240207463-A1 | RADIOACTIVE COMPLEX OF ANTI-EGFR ANTIBODY, AND RADIOPHARMACEUTICAL | EGFR, ERBB4, ERBB2 | TDP1 3570/4885EYA2 4581/4885APP 4595/4885 |
| US-20100183505-A1 | IMMUNOCONJUGATE FOR HUMAN CD66 FOR THE TREATMENT OF MULTIPLE MYELOMA AND OTHER HAEMATOLOGICAL MALIGNANCIES | CD63, CD47, CD22 | TDP1 3627/4885EYA2 2709/4885APP 4784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.